Martin Shkreli

{}irb

Martin Shkreli (born 1983) is an American hedge fund manager, specializing in healthcare, and is the founder of MSMB Capital Management, a multi-strategy hedge fund. ^[1] He is also Chairman and Chief Executive Officer of Retrophin LLC, a biotechnology firm founded in 2011. ^[2][3]

Early career

In 2000, Shkreli began working for Jim Cramer at Cramer, Berkowitz, & Co. He then spent three years at Intrepid Capital Management working in healthcare stock-picking under Steve Shapiro, a 'Tiger Cub' and protégé of Julian Robertson of Tiger Management.

Healthcare investing

Shkreli founded MSMB Capital Management (named after the two founding Portfolio Managers, Martin Shkreli and Marek Biestek) in 2009. ^[4]

Retrophin

Retrophin was created in February 2011 as a potential solution to Muscular Dystrophy.^[5] It was created and run from the offices of MSMB Capital as a portfolio company. Retrophin is engaged in an effort to get regulatory approval for what would be the first^{[citation needed]} muscular dystrophy drug ^[3]

References

1. ^ "MSMB Capital Management LLC Company Profile". BioPortfolio. Oct 26, 2011. http://www.bioportfolio.com/corporate/company/38758/Msmb-Capital-Management-Llc.html. 
2. ^ "MSMB Capital Makes Unsolicited $378M Bid For AMAG Pharmaceuticals". Bloomberg. Aug 3, 2011. http://www.bloomberg.com/news/2011-08-03/msmb-capital-offers-378-million-to-take-over-anemia-drug-maker-amag.html. 
3. ^ ^{a b} "Retrophin: About Us". http://www.retrophin.com/aboutus.html. 
4. ^ "Pfizer Board comes under fire". Financial Times. Dec 8, 2010. http://www.ft.com/intl/cms/s/0/9617888a-0300-11e0-bb1e-00144feabdc0.html#axzz1bvKabnxK. 
5. ^ "Retrophin Private Company Information". Business Week. Oct 26, 2011. http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=133551169.